Associated tags: TSX, Patient, Pharmaceutical industry, Methotrexate, Hematopoietic stem cell transplantation, Hematology, Customer service, Blood, Treosulfan, Rheumatoid arthritis, Allergy, Health Canada, FDA, Collaboration, World Health Organization, Glioma
Growth,
Patient,
Hematology,
Rheumatoid arthritis,
Telephone,
MD&A,
Treosulfan,
TSX,
Company,
Blood,
Health Canada,
GLOBE,
Customer service,
Allergy,
Review,
Methotrexate,
Hematopoietic stem cell transplantation,
Online shopping,
Pharmaceutical industry,
Collaboration TORONTO and CHICAGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (Medexus or the Company) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, February 10th, 2022, to discuss the Companys financial results for the fiscal 2022 third quarter ended December 31, 2021, as well as the Companys corporate progress and developments.
Key Points:
- TORONTO and CHICAGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (Medexus or the Company) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, February 10th, 2022, to discuss the Companys financial results for the fiscal 2022 third quarter ended December 31, 2021, as well as the Companys corporate progress and developments.
- The Company expects to file its financial statements along with its MD&A post market on February 9, 2022.
- The conference call will be available via telephone by dialing toll free 888-506-0062 for Canadian and U.S. callers or +1 973-528-0011 for international callers and by entering access code: 826598.
- Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform and a portfolio of proven best-in-class products.
Hematopoietic stem cell transplantation,
Treosulfan,
Methotrexate,
Haemophilia B,
Blood,
Growth,
Company,
Patient,
Gesellschaft mit beschränkter Haftung,
Conference,
TSX,
Hematology,
Degenerative disease,
GLOBE,
Rheumatoid arthritis,
Customer service,
Allergy,
Pharmaceutical industry,
Teamwork TORONTO and CHICAGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken dEntremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.
Key Points:
- TORONTO and CHICAGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken dEntremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.
- Medexus presentation will be available on-demand to registered attendees via the conference platform beginning Monday, January 10, 2022 at 7:00 AM Eastern Time.
- The webcast of the Companys presentation can be accessed here: https://journey.ct.events/view/f012aa0f-4cb0-49b5-b2f1-6dd5afd866ea and on the investor relations sections of Medexus website at medexus.com/investors as of 7:00 AM Eastern Time on Monday, January 10, 2022.
- Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform.
Retrieved on:
Thursday, December 2, 2021
Patient,
Gesellschaft mit beschränkter Haftung,
Conference,
Hematopoietic stem cell transplantation,
Treosulfan,
Company,
Sidoti,
Rheumatoid arthritis,
Blood,
TSX,
Degenerative disease,
Haemophilia B,
GLOBE,
Customer service,
Hematology,
Allergy,
Methotrexate,
Growth,
Pharmaceutical industry TORONTO and CHICAGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken dEntremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be participating in two upcoming virtual investor conferences.
Key Points:
- TORONTO and CHICAGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken dEntremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be participating in two upcoming virtual investor conferences.
- Mr. dEntremont and Mr. Konrad are scheduled to present on Wednesday, December 8, 2021 at 1:00 P.M. Eastern Time at the December Micro Cap Virtual Conference hosted by Sidoti.
- Mr. dEntremont and Mr. Konrad will be presenting at the SNN Network Canada Virtual Event.
- Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform.
Retrieved on:
Thursday, December 2, 2021
Patient,
Gesellschaft mit beschränkter Haftung,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Review,
Endpoint security,
CEO,
Hematopoietic stem cell transplantation,
Treosulfan,
Company,
Rheumatoid arthritis,
Health Canada,
Blood,
Urology,
TSX,
Degenerative disease,
Medac,
Haemophilia B,
Research,
Communication,
GLOBE,
Customer service,
NDA,
Hematology,
FDA,
Allergy,
Calendar,
Growth,
Methotrexate,
Food,
Pharmaceutical industry TORONTO and CHICAGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced that medac clarified with FDA details with regard to the projected NDA resubmission of treosulfan, an alkylating agent licensed from medac to Medexus, following its Type A Meeting with the U.S. Food and Drug Administration (“FDA”).
Key Points:
- Resubmission is required because the FDA previously issued a Complete Response Letter following their review of medacs original treosulfan NDA.
- Medexus and medac have reviewed the meeting minutes and the proposed pathway for resubmission.
- Ken dEntremont, CEO, stated, We are pleased with the outcome of medacs productive Type A Meeting with the FDA.
- Medexus expects the FDA to make a decision regarding approval of treosulfan within two to six months following the resubmission of the NDA.
Retrieved on:
Wednesday, November 10, 2021
NDA,
Mission statement,
Population,
Hematology,
Degenerative disease,
Methotrexate,
Adjustment,
Home After Three Months Away,
Pharmacy,
Hematopoietic stem cell transplantation,
Gesellschaft mit beschränkter Haftung,
Hand,
Haemophilia B,
Food,
Endpoint security,
SEDAR,
Blood,
Income,
Growth,
Investment,
Rheumatoid arthritis,
Trial,
Telephone,
Research,
Regulation of tobacco by the U.S. Food and Drug Administration,
Allergy,
Princess Margaret, Countess of Snowdon,
CRL,
CFO,
EBITDA,
Financial result,
TSX,
Company,
GLOBE,
New Drug Application,
Internal,
Treosulfan,
Six Months, Three Days,
Customer service,
Review,
Medac,
Patient,
FDA,
Haemophilia,
Animal,
Renewable energy,
Cryptocurrency,
Pharmaceutical industry,
Public relations,
Bookkeeping,
Security (finance) Second Quarter Fiscal 2022 Financial Highlights:
Key Points:
- Second Quarter Fiscal 2022 Financial Highlights:
Revenue of $17.9 million compared to $17.8 million for the same period last year.
- Cash and cash equivalents of $8.1 million with $9.6 million of available liquidity at September 30, 2021.
- Ken dEntremont, Chief Executive Officer of Medexus, commented, IXINITY ex-factory sales increased 14% in the three months ending September 30, 2021 vs. the three months ending June 30, 2021.
- Trecondyv(treosulfan in Canada): Medexus formalized its licensing agreement with medac for treosulfan in Canada on July 12, 2021.
Retrieved on:
Wednesday, November 10, 2021
Hematology,
Hematopoietic stem cell transplantation,
Investor relations,
Gesellschaft mit beschränkter Haftung,
Haemophilia B,
Blood,
Growth,
Rheumatoid arthritis,
Company,
Customer service,
Treosulfan,
Methotrexate,
Patient,
Allergy,
Degenerative disease,
Pharmaceutical industry A replay of the presentation will be available on the Investor Relations section of the Company website here .
Key Points:
- A replay of the presentation will be available on the Investor Relations section of the Company website here .
- The Investor Summit is an exclusive, independent conference dedicated to connecting small cap and microcap companies with qualified investors.
- The Q4 Investor Summit will take place virtually, featuring 80+ companies and over 800 investors, consisting of institutional investors, family offices, and private wealth.
- Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform.
Hematology,
University,
Hematopoietic stem cell transplantation,
Wilmer Cutler Pickering Hale and Dorr,
Gesellschaft mit beschränkter Haftung,
CEO,
Haemophilia B,
Blood,
Growth,
Rheumatoid arthritis,
WeWork,
TSX,
Company,
GLOBE,
Customer service,
Treosulfan,
Methotrexate,
Harvard Law School,
Patient,
Allergy,
Degenerative disease,
Pharmaceutical industry TORONTO and CHICAGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (Medexus or the Company) (TSX: MDP) (OTCQX: MEDXF) today announced that it has appointed IanC Wildgoose Brown as the Companys general counsel and corporate secretary.
Key Points:
- TORONTO and CHICAGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (Medexus or the Company) (TSX: MDP) (OTCQX: MEDXF) today announced that it has appointed IanC Wildgoose Brown as the Companys general counsel and corporate secretary.
- Before joining Medexus, Mr.Wildgoose Brown held senior positions with WeWork and its associated real estate investment platform, where his responsibilities included strategic transactional and corporate-development projects.
- Ken dEntremont, CEO of Medexus, stated, We are glad to have Mr. Wildgoose Brown join our team as general counsel.
- Medexus Pharmaceuticals is focused on the therapeutic areas of hematology, auto-immune disease, and allergy.
Retrieved on:
Thursday, November 4, 2021
Blood,
Treosulfan,
Haemophilia B,
Hematopoietic stem cell transplantation,
Patient,
Gesellschaft mit beschränkter Haftung,
Hematology,
Methotrexate,
MD&A,
Telephone,
TSX,
Allergy,
Company,
Growth,
Degenerative disease,
Rheumatoid arthritis,
GLOBE,
Customer service,
Pharmaceutical industry TORONTO and CHICAGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, November 11, 2021 to discuss the Companys financial results for the fiscal 2022 second quarter ended September 30, 2021, as well as the Companys corporate progress and other developments.
Key Points:
- TORONTO and CHICAGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, November 11, 2021 to discuss the Companys financial results for the fiscal 2022 second quarter ended September 30, 2021, as well as the Companys corporate progress and other developments.
- The Company expects to file its financial statements along with its MD&A post market on November 10, 2021.
- The conference call will be available via telephone by dialing toll free 888-506-0062 for Canadian and U.S. callers or +1 973-528-0011 for international callers and by entering access code: 329156.
- A webcast replay will be available on the Companys Investor Events section of the website ( https://www.medexus.com/en_US/investors/news-events ) through Friday, November 11, 2022.
Medac,
Blood,
Treosulfan,
New Drug Application,
Haemophilia B,
Hematopoietic stem cell transplantation,
Patient,
Gesellschaft mit beschränkter Haftung,
FDA,
Hematology,
Methotrexate,
Endpoint security,
Food,
Degenerative disease,
Health Canada,
TSX,
Allergy,
Review,
European Commission,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Urology,
CRL,
Royal commission,
Company,
CEO,
Growth,
Type,
Rheumatoid arthritis,
GLOBE,
Customer service,
Pharmaceutical industry The Type A Meeting has been scheduled to occur on November 23, 2021.
Key Points:
- The Type A Meeting has been scheduled to occur on November 23, 2021.
- As previously noted, these recommendations were covered by medacs existing development plan for treosulfan, which medac is contractually responsible to execute and fund.
- Ken dEntremont, CEO, commented, We have been actively working with medac to prepare for its anticipated Type A Meeting and are pleased that it has been granted this meeting in line with our previously anticipated timeline.
- Medexus Pharmaceuticals is focused on the therapeutic areas of hematology, auto-immune disease, and allergy.
Retrieved on:
Tuesday, October 26, 2021
Market capitalization,
Blood,
Treosulfan,
Haemophilia B,
Hematopoietic stem cell transplantation,
Patient,
Gesellschaft mit beschränkter Haftung,
Hematology,
Methotrexate,
TSX,
Allergy,
Conference,
Company,
Growth,
Degenerative disease,
Rheumatoid arthritis,
GLOBE,
Customer service,
Pharmaceutical industry TORONTO and CHICAGO and MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken dEntremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, are presenting at the Benzinga Global Small Cap Conference which is being held virtually on October 27-28, 2021.
Key Points:
- TORONTO and CHICAGO and MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken dEntremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, are presenting at the Benzinga Global Small Cap Conference which is being held virtually on October 27-28, 2021.
- Management is scheduled to present on Thursday, October 28th at 3:00 pm Eastern Time / 12:00 pm Pacific Time.
- The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders.
- Learn about small cap investing with clearly defined Educational Modules, take a look at a curated group of Small Cap investment opportunities, and connect with the global Small Cap audience in an intimate, virtual setting.
